NMIBC is becoming more prominent as its incidence is correlated with older age groups, with the median age being 70 when ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

LEO Pharma has reported topline outcomes from the Phase IIb trial of temtokibart, a potential new treatment for atopic ...

Vir is holding off on advancing the combination therapy to Phase III trials in hepatitis B until it secures a development ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

OmRx Oncology (OmRx) has commenced a Phase II trial for its OX-4224, targeting individuals with non-small cell lung cancer ...

GSK has reported positive outcomes from the Phase III GLISTEN trial of linerixibat for cholestatic pruritus (itch) and PBC.

Europe meeting, experts discussed the challenges and strategies of small and mid-sized biopharma companies surrounding ...

It is vital for biotech companies to run the right clinical trial and not cut costs, the Sanofi executive said.

Gilead Sciences has reported final outcomes from the Phase III MYR301 trial of bulevirtide for adults with chronic hepatitis ...

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

Andrzej Szandrach, Executive Director and Head of Study Management R&I at AstraZeneca , Dr. Martine Dehlinger-Kremer, vice president of Scientific Affairs ICON, and Dr. Ekaterina Dukokina, Head of ...